✦ LIBER ✦

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C

✍ Scribed by Shintaro Takaki; Akihito Tsubota; Tetsuya Hosaka; Norio Akuta; Takashi Someya; Masahiro Kobayashi; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada

Publisher: Springer Japan
Year: 2004
Tongue: English
Weight: 209 KB
Volume: 39
Category: Article
ISSN: 0944-1174
DOI: 10.1007/s00535-003-1363-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adequate timing of ribavirin reduction i

Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C

✍ Yasuji Arase; Kenji Ikeda; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Ma 📂 Article 📅 2004 🏛 Springer Japan 🌐 English ⚖ 171 KB

Mutations in the interferon sensitivity

Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection

✍ Mina Nakagawa; Naoya Sakamoto; Mayumi Ueyama; Kaoru Mogushi; Satoshi Nagaie; Yas 📂 Article 📅 2010 🏛 Springer Japan 🌐 English ⚖ 266 KB

Predictive factors of virological non-re

Predictive factors of virological non-response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load

✍ Norio Akuta; Fumitaka Suzuki; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; T 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract Patients with high viral load (≥1.0 × 10^5^ IU/ml) of hepatitis C virus (HCV) genotype 1b do not achieve high sustained virological response rates to interferon (IFN)/ribavirin combination therapy. Previous studies suggested that pretreatment amino acid (aa) substitution patterns in the

Combined treatment with interferon alpha

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

✍ R. Schvarcz; Z. B. Yun; A. Sönnerborg; O. Weiland 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB 👁 2 views

Ten patients with chronic hepatitis C, six of whom had not responded and four of whom had responded in a non-sustained fashion to interferon-alpha treatment alone, were given interferon alpha-2b and ribavirin in combination during 24 weeks. Interferon alpha-2b was given subcutaneously, at a dose of

Randomized trial of high-dose interferon

Randomized trial of high-dose interferon-α-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy

✍ Nami Mori; Michio Imamura; Yoshiiku Kawakami; Hiromi Saneto; Tomokazu Kawaoka; S 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 275 KB 👁 1 views

## Abstract The aim of this study was to compare the efficacy of high‐dose interferon (IFN)‐α‐2b with standard dose of IFN‐α‐2b in combination with ribavirin (RBV) for patients with chronic hepatitis C virus (HCV) infection, and to investigate the predictive factors associated with virological resp